<DOC>
	<DOC>NCT01238991</DOC>
	<brief_summary>The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind studies.</brief_summary>
	<brief_title>Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Subjects randomized under previous 3134K12202JA (NCT00752232) and 3134K12206JA (NCT00959192) and met all inclusion criteria and non of the exclusion criteria. Screening brain MRI scan is consistent with the diagnosis of AD. MMSE score 10 and above. Significant neurological diseases other than AD. Brain MRI evidence of vasogenic edema during the preceding studies. Clinically significant illness.</criteria>
	<gender>All</gender>
	<minimum_age>52 Years</minimum_age>
	<maximum_age>87 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>